In a recent conference call, management noted that they would be looking forward to discussing a registrational pathway with regulators for SGN-33a.
I have been following and investing in pharma and biotech for about 35 years, and I am not all that accustomed to hearing management referencing the topic of such talks following the reporting of results from a "merely" phase I study ( as, I believe will occur in December of this year....just three months away ).
If one is talking about discussing a registrational pathway with regulators, it would seem, perhaps, wise that you had better come to that particular table with some darn good cards in your hand. My feeling is that IF they do have those cards ( and we certainly do NOT know ), then they might want to be able to quickly execute and develop such a program without a partnering dilutive effect or else dip into funds dedicated to other important pipeline and label expansion assets.
Warning: The above should be considered pure and absolute SPECULATION. Ricardo has a huge long term share position in SGEN and he, at times, is not fully lucid due to his bias. He cannot be trusted or considered impartial in any way. Read what his says at your own peril.
Stock analysts at HC Wainright set a $65.00 price objective on shares of Seattle Genetics (NASDAQ:SGEN) stock in a report issued on Tuesday. The firm currently has a a “buy” rating on the stock.
In other Seattle Genetics news, Director Felix Baker purchased 950,886 shares of Seattle Genetics stock in a transaction that occurred on Thursday, May 21st. The shares were purchased at an average price of $42.49 per share, for a total transaction of $40,403,146.14. The purchase was disclosed in a document filed with the SEC....